Survival outcomes based on systemic agent used concurrently with radiation in human-papillomavirus associated oropharyngeal cancer

To investigate survival outcomes of patients treated with concurrent cetuximab and radiotherapy for primary management of both HPV positive and negative OPSCC, and compare the results to traditional platinum-based therapy. We hypothesize that the use of cetuximab in the HPV positive OPSCC patients will result in inferior survival based on tumor biological differences.A single institution retrospective analysis of 304 patients. The primary...